Streetbeat News

Price Targets

MRK

Wells Fargo analyst Mohit Bansal has maintained an Equal-Weight rating on Merck & Co (NYSE:MRK) and increased the price target from $125 to $130.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 2:16 pm

DECK

Raymond James analyst Rick Patel has maintained an Outperform rating on Deckers Outdoor (NYSE:DECK) and increased the price target from $845 to $925.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 2:15 pm

OCSL

Wells Fargo analyst Timothy O'Shea maintains an Overweight rating on Oaktree Specialty Lending (OCSL) but lowers the price target from $22 to $20.5.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 2:12 pm

AXS

Wells Fargo analyst Elyse Greenspan maintains an Underweight rating on Axis Capital Holdings (AXS) and raises the price target from $56 to $59.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 2:10 pm

HOLX

Raymond James analyst Andrew Cooper has maintained an Outperform rating on Hologic (NASDAQ:HOLX) and increased the price target from $85 to $88.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 2:10 pm

WEC

Wells Fargo analyst Neil Kalton has maintained an Overweight rating on WEC Energy Group (NYSE:WEC) but has lowered the price target from $93 to $91.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 2:05 pm

META

Raymond James analyst Josh Beck has maintained a Strong Buy rating on Meta Platforms (NASDAQ:META) and increased the price target from $450 to $550.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 2:04 pm

TPR

Wells Fargo analyst Ike Boruchow has maintained an Overweight rating on Tapestry (NYSE:TPR) and increased the price target from $50 to $60.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 2:04 pm

RVTY

Raymond James analyst Andrew Cooper has maintained an Outperform rating on Revvity (NYSE:RVTY) and increased the price target from $106 to $127.

Portfolio Pulse from Benzinga Newsdesk

February 02, 2024 | 2:01 pm

MRK

Merck & Co (NYSE:MRK) received mixed analyst ratings with an updated average 12-month price target of $133.75, reflecting a 2.88% increase from the previous target. The company's financial performance shows strong profitability and market presence, with a notable revenue growth rate of 6.71% as of September 30, 2023. Analysts' evaluations and adjustments in ratings and price targets indicate a positive outlook on Merck's stock, despite its revenue growth lagging behind industry peers.

Portfolio Pulse from Benzinga Insights

February 02, 2024 | 2:00 pm